A Modular Oncology Reference Model for Early Economic Evaluation: A Case Study in EGFR-Mutated NSCLC

In oncology HEOR, the methodological choices behind a cost-effectiveness estimate can shape decisions long before mature clinical data are available.

This poster presents a modular oncology reference model for early economic evaluation, demonstrated through a HER3-DXd case study in EGFR-mutated NSCLC. The model-derived progression-free survival hazard ratio closely matched the subsequent Phase 3 result, supporting the value of structured early-phase modeling to inform pricing, evidence generation, and payer engagement earlier in development.